FDA Allows Makers of Six COVID-19 Drugs To Provide Safety, Efficacy Results in Promotional Material

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Allows Makers of Six COVID-19 Drugs To Provide Safety, Efficacy Results in Promotional Material

J.W. Schomisch

November 17, 2022 at 04:37 PM EST

The FDA will allow the manufacturers of six COVID-19 drugs to provide some safety and efficacy results in promotional materials. A memorandum from the Center for Drug Evaluation and Research (CDER) revised “certain conditions on printed, advertising and promotional materials” for the Emergency Use Authorizations (EUA) of baricitinib, Actemra, Evusheld, Paxlovid, Lagevrio and ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Allows Makers of Six COVID-19 Drugs To Provide Safety, Efficacy Results in Promotional Material

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT